Tag: IR

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Targeted to Begin Generating Revenue Between Late 2028 and Mid-2029 Following Siemens Restoration at U.S. Facilities.

DALLAS, June 01, 2026 (GLOBE NEWSWIRE) -- Dave & Buster's Entertainment, Inc., (NASDAQ:PLAY), ("Dave & Buster's" or "the Company"), an owner, operator, and franchisor of entertainment and dining venues, today announced that it will report financial results for its first quarter ended May 5, 2026 after the market closes on Monday, June 15, 2026.

NEW CANAAN, Conn., June 01, 2026 (GLOBE NEWSWIRE) -- NewLake Capital Partners, Inc. (OTCQX: NLCP) (“NewLake or “the Company”), a leading provider of real estate capital to state-licensed cannabis operators, today announced that management will participate in the following June 2026 conferences.

Growing SHOP Acquisition Pipeline
Addition to the Russell 2000 and 3000 Indexes
Presentation at Nareit’s REITweek 2026 Investor Conference

Line-fit integration of the Viasat Hybrid SATCOM Approach for the C-130J presents opportunity to expand high-capacity, resilient connectivity across multi-mission airlift operations

„Ignitis grupė“ (toliau – Grupė) skelbia Grupės vadovo atranką, nes 2027 m. vasario 28 d. baigiasi dabartinio Grupės vadovo Dariaus Maikštėno antroji kadencija. Pagal Lietuvos Respublikos akcinių bendrovių įstatymą, valstybės valdomoje bendrovėje tas pats asmuo tos pačios bendrovės vadovu gali būti renkamas ne daugiau kaip dvi kadencijas iš eilės.

BEVERLY, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- ATN International, Inc. (“ATN”, the “Company”, “we”, “us”, and “our”) (Nasdaq: ATNI), a leading provider of digital infrastructure and communications services, today announced that management will participate in the 16^th Annual East Coast IDEAS Investor Conference at The Westin New York at Times Square on June 11, 2026.

Announces Progress in Second U.S. Department of War Program of Record Through Tier-1 Defense Partner Supporting the U.S. Army’s LASSO Program

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).